For estrogen receptor-positive and HER2 negative (ER+, HER2−) highly invasive breast cancer, an important new possibility to explore is represented by small molecule cyclin-dependent kinases (CDK4-6) inhibitors, such as abemaciclib, approved by FDA in September 2017 (Figure 2). Here, ESR1 is linked to breast cancer.